Opus Genetics (IRD) Free Cash Flow (2010 - 2026)

Opus Genetics (IRD) has 17 years of Free Cash Flow data on file, last reported at -$12.7 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 41.51% year-over-year to -$12.7 million in Q1 2026; TTM through Mar 2026 was -$39.0 million, a 35.11% decrease from a year earlier, with the FY2025 full-year figure at -$35.3 million, down 37.84% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$12.7 million, down from -$9.8 million in the prior quarter.
• Over the last five years, Free Cash Flow for IRD reached as high as $28.8 million in Q4 2022 and fell as low as -$12.7 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$3.6 million across 5 years, with a median of -$5.7 million in 2024.
• Across the five-year window, Free Cash Flow jumped 609.94% in 2022 and tumbled 837.31% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at $28.8 million in 2022, then sank by 84.2% to $4.5 million in 2023, then slumped by 263.54% to -$7.4 million in 2024, then plunged by 32.2% to -$9.8 million in 2025, then dropped by 29.43% to -$12.7 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$12.7 million in Q1 2026, -$9.8 million in Q4 2025, and -$6.2 million in Q3 2025.